

September 9, 2010

Peregrine Pharmaceuticals Reports First Quarter Fiscal Year 2011 Clinical Progress and Financial Results

Advancing Phase II Oncology Programs for Bavituximab and Cotara(R)

TUSTIN, CA, Sep 09, 2010 (MARKETWIRE via COMTEX News Network) -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced its clinical progress and financial results for the first quarter ended July 31, 2010 for its fiscal year (FY) 2011 and provided an update on the progress with its development programs.

"Our broad-spectrum Phase II bavituximab oncology program and our Phase II Cotara(R) brain cancer program represent key future value drivers for Peregrine," said Steven W. King, president and chief executive officer of Peregrine. "Advancing these clinical programs remains our top priority and during this past quarter we achieved multiple milestones, with positive Phase II data in lung, advanced breast, and brain cancers. Driven by these data, we recently launched two randomized Phase II b non-small cell lung cancer (NSCLC) trials for bavituximab and made significant strides toward completing our Phase II glioblastoma multiforme trial for Cotara. Each of these three clinical programs is a potential value inflection point for Peregrine and represents an independent regulatory path toward potential product approval. Our integrated biomanufacturing subsidiary Avid Bioservices, which is expected to generate between \$8 and \$12 million in third-party contract manufacturing revenue during fiscal year 2011, reduces our operational expenses while it prepares for potential future clinical development and commercial launch should our clinical programs be successful."

Oncology Program Highlights

Bavituximab Phase IIb Cancer Trials Based on promising clinical data presented this year at the American Society of Clinical Oncology (ASCO) 2010 Annual Meeting in June, Peregrine launched a randomized, placebo-controlled, double-blinded Phase IIb trial in refractory NSCLC and expects to unblind top-line data by the end of 2011. In addition, Peregrine has initiated a randomized open-label Phase IIb trial in front-line NSCLC. The second study is an open label study and Peregrine expects to periodically report objective response rate data as patients are enrolled and interim data analysis is completed. Enrollment in both trials is expected to be complete by mid-year 2011.

At the ASCO 2010 Annual Meeting, Peregrine presented encouraging overall response rate (ORR) and median progressionfree survival (PFS) data from three Phase II trials and expects to report final data once available.

- -- Phase II front-line NSCLC trial showed ORR of 43% of patients (n=49) and median PFS of 6.1 months for patients treated with bavituximab in combination with carboplatin and paclitaxel. These results exceed the 15% ORR and 4.5 month median PFS of carboplatin and paclitaxel alone from a separate historical trial.
- -- Phase II front-line advanced breast cancer trial showed ORR of 74% of patients (n=46) and median PFS of 6.9 months for patients treated with bavituximab in combination with carboplatin and paclitaxel. These results exceed the 62% ORR and 4.8 month median PFS of carboplatin and paclitaxel alone from a separate historical trial.
- -- Phase II refractory advanced breast cancer trial showed ORR of 61% of patients (n=46) and median PFS of 7.4 months for patients treated with bavituximab in combination with docetaxel. This exceeds the 41% ORR of docetaxel alone from a separate historical trial.

Cotara(R) Phase II Brain Cancer Trial By year-end, Peregrine expects to complete enrollment in its Phase II safety and efficacy trial of Cotara in up to 40 patients with recurrent glioblastoma multiforme (GBM). Previously reported interim data from two separate Phase II studies showed median survival ranging from 38 to 41 weeks, compared to 24 weeks for historical control, in this deadliest form of brain cancer.

Antiviral Program Highlights

Bavituximab Phase Ib HCV Infection Trial Peregrine expects to complete enrollment by year-end in its Phase Ib safety and efficacy trial of bavituximab monotherapy in up to 24 patients coinfected with hepatitis C virus (HCV) and HIV. As clinical data to date have been encouraging and preclinical data support advancing bavituximab's development for HCV, the company is considering potential next steps for clinical development.

Government-Sponsored Research Peregrine's contract (HDTRA1-08-C-0003) with the Transformational Medical Technologies (TMT) program of the U.S. Department of Defense's Defense Threat Reduction Agency (DTRA) has provided for up to \$22.3 million in funding during the two-year base period ending June 29, 2010 and potentially provides for a total of up to \$44.4 million over a five-year period. The two-year based period has been extended by several weeks while Peregrine works closely with the government to determine the scope and timing of the further evaluation of its phosphatidylserine (PS)-targeting antibodies in advanced models of viral hemorrhagic fever (VHF) infections.

Intellectual Property

Peregrine strengthened its proprietary position in targeting PS when two U.S. patents were issued, providing protection for vascular imaging and antiviral applications of a broad range of phospholipid-targeting antibodies. These two new patents cover vascular imaging using PS and phosphatidylethanolamine (PE)-targeting antibodies and certain other proteins and composition and viral treatment methods of a broad range of antibodies, including bavituximab and fully human counterparts to bavituximab.

Financial Results

Total revenues for the first quarter of FY 2011 were \$3,209,000, compared to \$6,750,000 for the same quarter of the prior fiscal year. This decrease was primarily attributed to a reduction in government contract revenue due to the timing and scope of research activities performed under Peregrine's government contract. In addition, contract manufacturing revenue from Peregrine's subsidiary Avid Bioservices decreased due to a reduction in the level and timing of services provided to third-party customers compared to the same period of the prior year. Avid will continue to utilize available capacity and resources to begin preparing for the future clinical development and potential commercialization of bavituximab, while also seeking to grow its base of third-party clients.

Total costs and expenses in the first quarter of FY 2011 were \$10,721,000, compared to \$8,940,000 in the first quarter of FY 2010. The increase was attributable to higher research and development and selling, general administrative expenses, primarily to support Peregrine's two Phase IIb bavituximab NSCLC trials. For the first quarter FY 2011, research and development expenses were \$7,067,000, compared to \$6,074,000 for the first quarter of FY 2010.

Peregrine's consolidated net loss was \$7,695,000, or \$0.14 per share, for the first quarter of FY 2011, compared to a net loss of \$2,428,000 or \$0.05 per share, for the same quarter of the prior year.

Peregrine reported \$17,983,000 in cash and cash equivalents at July 31, 2010, compared to \$19,681,000 at April 30, 2010, and \$12,778,000 at July 31, 2009.

More detailed financial information and analysis may be found in Peregrine's Quarterly Report on Form 10-Q, which was filed with the Securities and Exchange Commission today.

Conference Call Peregrine will host a conference call and webcast today, September 9, 2010, at 4:30 p.m. EDT (1:30 p.m. PDT).

- -- To listen to the live webcast or access the archived webcast available for 30 days, please visit: www.peregrineinc.com.
- -- To listen to the conference call, please call (877) 312-5443 or (253) 237-1126 and request the Peregrine Pharmaceuticals call. A replay of the call will be available starting approximately one hour after the conclusion of the call through September 16, 2010 by calling (800) 642-1687 or (706) 645-9291 and using passcode 96261019.

About Peregrine Pharmaceuticals Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing multiple clinical programs in cancer and hepatitis C virus infection with its lead product candidate bavituximab and novel brain cancer agent Cotara(R). Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forwardlooking statements involve risks and uncertainties including, but not limited to, the risk the company may experience delays in clinical trial patient enrollment, the risk that the results of the Phase IIb clinical trials may not correlate with the results from prior clinical and preclinical studies, the risk that the company may not have or be able to raise sufficient financial resources to complete the Phase IIb trials, the risk that Avid's revenue growth may slow or decline, the risk that Avid may experience technical difficulties in processing customer orders which could delay delivery of products to customers and receipt of payment, the risk that one or more existing Avid customers terminates its contract prior to completion, and the risk that the government contract with the TMT may not be further extended or provide any additional funding. It is important to note that the Company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the fiscal year ended April 30, 2010 and quarterly report on Form 10-Q for the quarter ended July 31, 2010. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

PEREGRINE PHARMACEUTICALS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS

	THREE MONTHS ENDED			
	2010			
	Unaudited	Unaudited		
REVENUES	* 000 000	* 0 0		
Contract manufacturing revenue	\$ 983,000			
Government contract revenue		4,671,000		
License revenue	115,000			
Total revenues		6,750,000		
COSTS AND EXPENSES:				
Cost of contract manufacturing	1,156,000	1,073,000		
Research and development	7,067,000	6,074,000		
Selling, general and administrative	2,498,000	1,793,000		
Total costs and expenses		8,940,000		
LOSS FROM OPERATIONS	(7,512,000)	(2,190,000)		
OTHER INCOME (EXPENSE):				
Interest and other income	18,000	40,000		
Interest and other expense		(278,000)		
NET LOSS		\$ (2,428,000)		
	============			
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING	54,357,574 46,808,791			
	=======================================			
BASIC AND DILUTED LOSS PER COMMON SHARE	\$ (0.14) =========	\$ (0.05)		
PEREGRINE PHARMACEUTICALS, INC.				
CONDENSED CONSOLIDATED BALANCE SHEETS				
CONDENSED CONSOLIDATED BALANCE SHEETS	JULLY 31	APRIL 30,		
	2010	2010		
	2010	2010		

Unaudited

rade and other receivables, net overnment contract receivables (4,692,000) 3,123,000 bit issuance costs, current portion Total current assets ROPERTY: assehold improvements shoratory equipment 4,278,000 4,221,000 routing a spense and other current assets, net 1,703,000 2,6,778,000 26,574,000 26,778,000 4,221,000 1,364,000 917,000 4,221,000 1,465,000 917,000 1,485,000 917,000 4,221,000 1,465,000 917,000 1,465,000 (4,266,000) Property, net 1,651,000 1,465,000 1,088,000 1,067,000 ther assets 1,096,000 1,067,000 1,088,000 1,068,000 21,000 1,088,000 1,067,000 1,088,000 1,067,000 1,088,000 1,068,000 1,068,000 0,000 ther assets 1,096,000 1,088,000 1,088,000 1,088,000 1,088,000 1,088,000 1,088,000 1,088,000 1,088,000 1,088,000 1,088,000 1,088,000 1,088,000 1,088,000 1,088,000 1,088,000 1,088,000 1,088,000 1,088,000 1,088,000 1,088,000 1,088,000 1,088,000 1,088,000 1,088,000 1,088,000 1,088,000 1,088,000 1,088,000 1,088,000 1,088,000 1,088,000 1,088,000 1,088,000 1,088,000 1,088,000 1,088,000 1,088,000 1,088,000 1,088,000 1,088,000 1,088,000 1,088,000 1,088,000 1,088,000 1,088,000 1,088,000 1,088,000 1,088,000 1,088,000 1,088,000 1,088,000 1,088,000 1,088,000 1,088,000 1,088,000 1,088,000 1,088,000 1,088,000 1,088,000 1,088,000 1,088,000 1,088,000 1,088,000 1,088,000 1,088,000 1,088,000 1,088,000 1,088,000 1,088,000 1,088,000 1,088,000 1,088,000 1,088,000 1,088,000 1,088,000 1,080,000 1,080,000 1,080,000 1,080,000 1,080,000 1,080,000 1,080,000 1,080,000 1,080,000 1,080,000 1,080,000 1,080,000	CURRENT ASSETS:		
rade and other receivables, net overnment contract receivables, net overnment contract receivables novemtories, net tissuance costs, current portion repaid expenses and other current assets, net Total current assets ROPERTY: assehold improvements aboratory equipment aboratory equipment software roperty, net Troperty, net Trotal other assets ROMENTS: ess accumulated depreciation and amortization Total other assets ROMENTS: ess accumulated depreciation and amortization Total other assets ROMENTS: ess accumulated negreciation and amortization Total other assets ROMENTS: ess accumulated negreciation and amortization Total other assets ROMENTS: est issuance costs, less current portion ther assets ROMENTS: est issuance costs, less current portion Total other assets ROMENTS: est issuance costs, INC. DNDENSED CONSOLIDATED BALANCE SHEETS (continued) JULY 31, APRIL 30, 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 201	Cash and cash equivalents	\$ 17,983,000	\$ 19,681,000
nventories, net 4,692,000 3,122,000 abt issuance costs, current portion 94,000 122,000 abt assuance costs, current portion 1,703,000 2,004,000 Total current assets 26,354,000 26,778,000 aboratory equipment 4,278,000 4,221,000 urniture, fixtures, office equipment and 1,364,000 917,000 assetsd 1,364,000 917,000 ess accumulated depreciation and amortization (4,504,000) (4,268,000) Property, net 1,851,000 1,469,000 Title ASSETS: 1,966,000 1,088,000 bit issuance costs, less current portion 8,000 1,067,000 Total other assets 1,096,000 1,088,000 Total other assets 1,096,000 1,088,000 SILL ASSETS \$ 29,301,000 \$ 29,333,000 Contract Structures JULY 31, AFRIL 30, Contract Structures 1,762,000 \$ 2,259,000 Corued clinical trial site fees 1,762,000 \$ 2,259,000 Corued payroll and related costs 1,773,000 <td< td=""><td>rade and other receivables, net</td><td>1,292,000</td><td>1,481,000</td></td<>	rade and other receivables, net	1,292,000	1,481,000
nventories, net 4,692,000 3,122,000 abt issuance costs, current portion 94,000 122,000 abt assuance costs, current portion 1,703,000 2,004,000 Total current assets 26,354,000 26,778,000 aboratory equipment 4,278,000 4,221,000 urniture, fixtures, office equipment and 1,364,000 917,000 assetsd 1,364,000 917,000 ess accumulated depreciation and amortization (4,504,000) (4,268,000) Property, net 1,851,000 1,469,000 Title ASSETS: 1,966,000 1,088,000 bit issuance costs, less current portion 8,000 1,067,000 Total other assets 1,096,000 1,088,000 Total other assets 1,096,000 1,088,000 SILL ASSETS \$ 29,301,000 \$ 29,333,000 Contract Structures JULY 31, AFRIL 30, Contract Structures 1,762,000 \$ 2,259,000 Corued clinical trial site fees 1,762,000 \$ 2,259,000 Corued payroll and related costs 1,773,000 <td< td=""><td>Government contract receivables</td><td>590,000</td><td>367,000</td></td<>	Government contract receivables	590,000	367,000
bet issuance costs, current portion 94,000 122,000 repaid expenses and other current assets, net 1,703,000 2,004,000 Total current assets 26,354,000 26,778,000 ROPERTY: 26,354,000 4,221,000 assehold improvements 713,000 697,000 aboratory equipment 4,278,000 4,221,000 urniture, fixtures, office equipment and 1,364,000 917,000 assets 1,364,000 917,000 ess accumulated depreciation and amortization (4,504,000) (4,366,000) Property, net 1,851,000 1,469,000 Total other assets 1,066,000 1,088,000 Total other assets 1,066,000 1,088,000 Total other assets 1,066,000 1,088,000 Total other assets 1,074,000 2,210 DODENSED CONSOLIDATED BALANCE SHEETS (continued) JULY 31, APRIL 30, 2010 2010 Coruce payable, current portion and net of 1,762,000 2,666,000 Coruce payable, current portion and net of 1,946,000 1,893,000 Eferred revenue	Inventories, net		
repaid expenses and other current assets, net 1,703,000 2,004,000 Total current assets 26,354,000 26,778,000 ROPERTY: assehold improvements 713,000 697,000 aboratory equipment 4,278,000 4,221,000 urniture, fixtures, office equipment and 1,364,000 917,000 software 1,364,000 917,000 essehold improvements 1,364,000 917,000 essence 1,851,000 1,469,000 essence costs, less current portion 8,000 1,067,000 Total other assets 1,096,000 1,088,000 OTAL ASSETS \$ 29,301,000 \$ 29,335,000 EREGRINE PHARMACEUTICALS, INC. JULY 31, APRIL 30, 2010 DOTAL ASSETS \$ 2,661,000 \$ 2,259,000 Corued clinical trial site fees 1,762,000 \$ 2,666,000 Corued clinical trial site fees 1,799,000 2,406,000 discount 1,946,000 1,623,000 efferred revenue 3,719,000 2,618,000 efferred government contract revenue 47,000 7,800 fiscount 1,946,000 1,946,			
Total current assets 26,354,000 26,778,000 ROPERTY: aboratory equipment 713,000 697,000 aboratory equipment 4.278,000 4.221,000 urniture, fixtures, office equipment and 1,364,000 917,000 offware	-	1,703,000	2,004,000
ROPRETY: 713,000 697,000 basehold improvements 713,000 697,000 software 1,364,000 917,000 urniture, fixtures, office equipment and	Total current assets		
aboratory equipment 4,278,000 4,221,000 urniture, fixtures, office equipment and software 1,364,000 917,000 	PROPERTY:		
urniture, fixtures, office equipment and software 1,364,000 917,000 software	Leasehold improvements	713,000	697,000
software 1,364,000 917,000 ess accumulated depreciation and amortization (4,504,000) (4,366,000) Property, net 1,851,000 1,469,000 THER ASSETS: 1,086,000 1,048,000 bt issuance costs, less current portion 8,000 21,000 Total other assets 1,096,000 1,088,000 DTAL ASSETS \$ 29,301,000 \$ 29,335,000 EREGRINE PHARMACEUTICALS, INC. JULY 31, APRIL 30, 2010 DNDENSED CONSOLIDATED BALANCE SHEETS (continued) JULY 31, APRIL 30, 2010 Carued clinical trial site fees 1,762,000 2,666,000 carued payroll and related costs 1,773,000 1,623,000 discount 1,946,000 1,893,000 eferred revenue 47,000 78,000 ottes payable, current portion and net of 15,158,000 14,403,000 ottes payable, less current portion and net of 1,339,000 860,000 ferred revenue 1,039,000 860,000	Laboratory equipment	4,278,000	4,221,000
6,355,000 5,835,000 Property, net 1,851,000 (4,364,000) Property, net 1,851,000 1,469,000 THER ASSETS: 1,088,000 1,067,000 bt issuance costs, less current portion 8,000 1,067,000 Total other assets 1,096,000 1,088,000 29,335,000 OTAL ASSETS \$ 29,301,000 \$ 29,335,000 2010 2010 Total other assets 1,096,000 1,088,000 2010 2010 OTAL ASSETS \$ 29,301,000 \$ 29,335,000 2010 2010 2010 Could construct the assets 1,096,000 1,088,000 2010 2010 2010 Could construct the assets 1,096,000 1,083,000 2,259,000 2,000 2,000,000 2,000,000 2,000,000 2,000,000 2,000,000 2,000,000 2,000,000 2,000,000 2,000,000 2,000,000 2,000,000 2,000,000 2,000,000 2,000,000 2,000,000 2,000,000 2,000,000 2,000,000 2,000,000 2,000,000 2,000,000 <	Furniture, fixtures, office equipment and		
6,355,000 5,835,000 ess accumulated depreciation and amortization (4,504,000) (4,366,000) Property, net 1,851,000 1,469,000 THER ASSETS: 1,096,000 1,067,000 Total other assets 1,096,000 1,068,000 OTAL ASSETS \$ 29,301,000 \$ 29,335,000 Total other assets \$ 29,301,000 \$ 29,335,000 OTAL ASSETS \$ 2010 2010 Construction JULY 31, APRIL 30, Z010 2010 2010 Construction 1,762,000 \$ 2,666,000 Corrued clinical trial site fees 1,773,000 1,623,000 discount 1,946,000 1,893,000 eferred revenue 3,719,000 2,406,000 eferred dovernment contract revenue 47,000 78,000 ottal current liabilities 15,158,000 1,44,30,000 ottal current liabilities 15,158,000 1,403,000 ottal current liabilities 15,158,000 - ottal current liabilities 169,000 210,000	software		
ess accumulated depreciation and amortization (4,504,000) (4,366,000) Property, net 1,851,000 1,469,000 THER ASSETS: bt issuance costs, less current portion 8,000 21,000 ther assets 1,096,000 1,068,000 CTAL ASSETS \$29,301,000 \$29,335,000 CTAL ASSETS \$29,301,000 \$29,335,000 CTAL ASSETS \$29,301,000 \$29,335,000 CTAL ASSETS \$2010 2010 CONDENSED CONSOLIDATED BALANCE SHEETS (continued) UNRENT LIABLITIES: CCOUNTS payable \$2,681,000 \$2,259,000 CCrued clinical trial site fees 1,762,000 2,666,000 CCrued payroll and related costs 1,773,000 1,623,000 efferred revenue 3,719,000 2,406,000 efferred government contract revenue 47,000 78,000 ustomer deposits 2,191,000 2,618,000 ther current liabilities 15,158,000 14,403,000 efferred revenue 125,000 - Total current liabilities 15,158,000 120,000 efferred stock-\$0.01 par value; authorized 352,000,000 shares; outstanding - 55,784,955 and 53,094,896, respectively 56,000 275,208,000 cumulated deficit - Current - Total current capital 282,330,000 275,208,000 cumulated deficit - Current - Current -			
Property, net 1,851,000 1,469,000 THER ASSETS: 1,0851,000 1,067,000 cht issuance costs, less current portion 8,000 21,000 Total other assets 1,096,000 1,088,000 Contact other assets 1,096,000 1,088,000 Total other assets 1,096,000 1,088,000 Contact other assets 1,010 2010 Contact other assets 1,010 2,259,000 Corust payable \$ 2,681,000 \$ 2,259,000 Corust payable, current portion and net of 1,946,000 1,893,000 cferred government contract revenue 47,700 78,000 cherred government contract revenue 1,039,000 2,618,000 cherred scouth 11,946,000 1,315,000 of di			
THER ASSETS: 8,000 21,000 ther assets 1,088,000 1,067,000 Total other assets 1,096,000 1,088,000 OTAL ASSETS \$ 29,301,000 \$ 29,335,000 DTAL ASSETS \$ 2010 \$ 2010 EREGRINE PHARMACEUTICALS, INC. JULY 31, APRIL 30, 2010 2010 ONDENSED CONSOLIDATED BALANCE SHEETS (continued) JULY 31, APRIL 30, 2010 2,259,000 Carued clinical trial site fees 1,762,000 2,666,000 Carued payroll and related costs 1,773,000 1,623,000 otes payable, current portion and net of 1,946,000 1,893,000 discount 1,946,000 1,893,000 860,000 eferred revenue 2,191,000 2,618,000 660,000 ottes payable, current portion and net of 1,033,000 860,000 discount 1,946,000 1,893,000 860,000 ottes payable, less current portion and net 1,039,000 860,000 ottes payable, less current portion and net 1,219,000 2,618,000 ottes payable, less current portion and net 12,000 1,315,000 of discount 712,000 <	less accumulated depreciation and amortization		
THER ASSETS: 8,000 21,000 ther assets 1,088,000 1,067,000 Total other assets 1,096,000 1,088,000 OTAL ASSETS \$ 29,301,000 \$ 29,335,000 DTAL ASSETS \$ 2010 \$ 2010 EREGRINE PHARMACEUTICALS, INC. JULY 31, APRIL 30, 2010 2010 ONDENSED CONSOLIDATED BALANCE SHEETS (continued) JULY 31, APRIL 30, 2010 2,259,000 Carued clinical trial site fees 1,762,000 2,666,000 Carued payroll and related costs 1,773,000 1,623,000 otes payable, current portion and net of 1,946,000 1,893,000 discount 1,946,000 1,893,000 860,000 eferred revenue 2,191,000 2,618,000 660,000 ottes payable, current portion and net of 1,033,000 860,000 discount 1,946,000 1,893,000 860,000 ottes payable, less current portion and net 1,039,000 860,000 ottes payable, less current portion and net 1,219,000 2,618,000 ottes payable, less current portion and net 12,000 1,315,000 of discount 712,000 <	Property, net		
ebt issuance costs, less current portion8,00021,000ther assets1,088,0001,067,000Total other assets1,096,0001,088,000DTAL ASSETS\$ 29,301,000\$ 29,335,000EREGRINE PHARMACEUTICALS, INC.JULY 31, APRIL 30, 20102010CONDENSED CONSOLIDATED BALANCE SHEETS (continued)JULY 31, APRIL 30, 20102010TABILITIES AND STOCKHOLDERS' EQUITYUnauditedURRENT LIABILITIES: cocurds payable\$ 2,681,000\$ 2,259,000 2,666,000ccrued payroll and related costs1,773,0001,623,000otes payable, current portion and net of discount1,946,0001,893,000eferred revenue3,719,0002,406,000eferred revenue1,039,000860,000ther current liabilities15,158,00014,403,000otes payable, less current portion and net of discount712,0001,315,000otes payable, less current portion and net of discount712,000	OTHER ASSETS:		
ther assets 1,088,000 1,067,000 Total other assets 1,096,000 1,088,000 DTAL ASSETS \$ 22,301,000 \$ 29,335,000 EREGRINE PHARMACEUTICALS, INC. ONDENSED CONSOLIDATED BALANCE SHEETS (continued) DULY 31, APRIL 30, 2010 2010 	Debt issuance costs, less current portion	8,000	21,000
Total other assets 1,096,000 1,088,000 OTAL ASSETS \$29,301,000 \$29,335,000 EREGRINE PHARMACEUTICALS, INC. ONDENSED CONSOLIDATED BALANCE SHEETS (continued) JULY 31, APRIL 30, 2010 2010 	Other assets		
OTAL ASSETS\$ 29,301,000\$ 29,335,000EREGRINE PHARMACEUTICALS, INC.JULY 31, APRIL 30, 20102010DNDENSED CONSOLIDATED BALANCE SHEETS (continued)JULY 31, APRIL 30, 2010IABLANCE SHEETS (continued)JULY 31, APRIL 30, 2010UnauditedIABLANCE SHEETS (continued)IABLLITIES AND STOCKHOLDERS' EQUITYUnauditedURRENT LIABILITIES: ccounts payable\$ 2,681,000\$ 2,259,000 2,666,000ccrued clinical trial site fees1,762,0002,666,000ccrued payroll and related costs1,773,0001,623,000oferred revenue3,719,0002,406,000eferred government contract revenue47,00078,000ustomer deposits2,191,0002,618,000ther current liabilities15,158,00014,403,000otd discount712,0001,315,000eferred revenue712,0001,315,000of discount712,0001,315,000eferred stock-\$0.001 par value; authorized5,000210,000common stock-\$0.001 par value; authorized5,00053,00025,000,000 shares; outstanding55,784,955 and 53,094,896, respectively56,00053,000dditional paid-in capital282,330,000275,208,000ccumulated deficit282,330,000275,208,000			
OTAL ASSETS\$ 29,301,000\$ 29,335,000EREGRINE PHARMACEUTICALS, INC.JULY 31, APRIL 30, 20102010DNDENSED CONSOLIDATED BALANCE SHEETS (continued)JULY 31, APRIL 30, 2010IABLANCE SHEETS (continued)JULY 31, APRIL 30, 2010UnauditedIABLANCE SHEETS (continued)IABLLITIES AND STOCKHOLDERS' EQUITYUnauditedURRENT LIABILITIES: ccounts payable\$ 2,681,000\$ 2,259,000 2,666,000ccrued clinical trial site fees1,762,0002,666,000ccrued payroll and related costs1,773,0001,623,000oferred revenue3,719,0002,406,000eferred government contract revenue47,00078,000ustomer deposits2,191,0002,618,000ther current liabilities15,158,00014,403,000otd discount712,0001,315,000eferred revenue712,0001,315,000of discount712,0001,315,000eferred stock-\$0.001 par value; authorized5,000210,000common stock-\$0.001 par value; authorized5,00053,00025,000,000 shares; outstanding55,784,955 and 53,094,896, respectively56,00053,000dditional paid-in capital282,330,000275,208,000ccumulated deficit282,330,000275,208,000	Total other assets	1,096.000	1,088.000
EREGRINE PHARMACEUTICALS, INC. ONDENSED CONSOLIDATED BALANCE SHEETS (continued) JULY 31, APRIL 30, 2010 2010 	TOTAL ASSETS		
EREGRINE PHARMACEUTICALS, INC. ONDENSED CONSOLIDATED BALANCE SHEETS (continued) JULY 31, APRIL 30, 2010 2010 			
JULY 31, APRIL 30, 2010 2010 	PEREGRINE PHARMACEUTICALS, INC.		
20102010UnauditedIABILITIES AND STOCKHOLDERS' EQUITYUnauditedURRENT LIABILITIES:ccounts payable\$ 2,681,000 \$ 2,259,000ccounts payable\$ 2,681,000 \$ 2,259,000ccounts payable\$ 2,681,000 \$ 2,259,000ccounts payable\$ 2,681,000 \$ 2,259,000ccounts payable, current portion and net ofdiscount1,773,000 1,623,000discount1,946,000 1,893,000eferred revenue47,000 78,000eferred government contract revenue47,000 78,000there current liabilities2,191,000 2,618,000Total current liabilities15,158,000 14,403,000otes payable, less current portion and netof discountTotal current liabilities15,158,000 14,403,000otes payable, less current portion and netof 22,000210,000otes payable, less current portion and netof 22,000210,000otes payable, less current portion and netOT2,0001,315,000otes payable, less current portion and netOT2,0001,315,000OTCKHOLDERS' EQUITY:referred stock-\$0.001 par value; authorized5,000,000 shares; non-voting; nil sharesoutstandingoutstanding	CONDENSED CONSOLIDATED BALANCE SHEETS (continue		
IABILITIES AND STOCKHOLDERS' EQUITYUnauditedUnauditedURRENT LIABILITIES: ccounts payable\$ 2,681,000 \$ 2,259,000ccounts payable, current portion and net ofdiscount1,946,000 1,893,000eferred revenue\$ 7,19,000 2,618,000of discount\$ 2,191,000 2,618,000Total current liabilities\$ 2,191,000 2,618,000Total current liabilities\$ 15,158,000 14,403,000of discount\$ 712,000 1,315,000eferred revenue\$ 125,000 -of discount\$ 125,000 -of discount\$ 269,000 210,000ormitiments and contingenciesrock-\$0.001 par value; authorized\$ 5,000,000 shares; non-voting; nil shares\$ 56,000 53,000outstandingormition and paid-in capital282,330,000 275,208,000(269,549,000) (261,854,000)		JULY 31,	APRIL 30,
Unaudited IABILITIES AND STOCKHOLDERS' EQUITY URRENT LIABILITIES: ccounts payable \$ 2,681,000 \$ 2,259,000 ccrued clinical trial site fees 1,762,000 2,666,000 ccrued payroll and related costs 1,773,000 1,623,000 otes payable, current portion and net of discount 1,946,000 1,893,000 eferred revenue 3,719,000 2,406,000 eferred government contract revenue 47,000 78,000 ther current liabilities 2,191,000 2,618,000 ther current liabilities 1,039,000 860,000 Total current liabilities 15,158,000 14,403,000 otes payable, less current portion and net of discount 712,000 1,315,000 - ther long-term liabilities 469,000 210,000 ommitments and contingencies TOCKHOLDERS' EQUITY: referred stock-\$0.001 par value; authorized 55,000,000 shares; non-voting; nil shares outstanding - ommon stock-\$0.001 par value; authorized 325,000,000 shares; outstanding - 55,784,955 and 53,094,896, respectively 56,000 275,208,000 ccumulated deficit (269,549,000) (261,854,000)			
IABILITIES AND STOCKHOLDERS' EQUITYURRENT LIABILITIES:\$ 2,681,000 \$ 2,259,000corued clinical trial site fees1,762,000 2,666,000corued payroll and related costs1,773,000 1,623,000cotes payable, current portion and net of1,946,000 1,893,000discount1,946,000 1,893,000eferred revenue3,719,000 2,406,000eferred government contract revenue47,000 78,000ustomer deposits2,191,000 2,618,000ther current liabilities15,158,000 14,403,000otes payable, less current portion and net15,158,000 14,403,000of discount712,000 1,315,000eferred revenue125,000 -ther long-term liabilities469,000 210,000ommintments and contingencies-TOCKHOLDERS' EQUITY:-referred stock-\$0.001 par value; authorized-50,000,000 shares; non-voting; nil shares-outstanding-common stock-\$0.001 par value; authorized-25,784,955 and 53,094,896, respectively56,000 53,000dditional paid-in capital282,330,000 275,208,000ccumulated deficit(269,549,000) (261,854,000)	-		
URRENT LIABILITIES:ccounts payable\$ 2,681,000 \$ 2,259,000ccrued clinical trial site fees1,762,000 2,666,000ccrued payroll and related costs1,773,000 1,623,000otes payable, current portion and net of1,946,000 1,893,000discount1,946,000 1,893,000eferred revenue47,000 78,000ustomer deposits2,191,000 2,618,000ther current liabilities1,039,000 860,000Total current liabilities15,158,000 1,403,000otes payable, less current portion and net15,158,000 1,315,000of discount712,000 1,315,000eferred revenue125,000 -of discount125,000 -ferred revenue469,000 210,000ommon stock-\$0.001 par value; authorized50,000 53,00025,784,955 and 53,094,896, respectively56,000 53,000dditional paid-in capital282,330,000 275,208,000ccurulated deficit(269,549,000) (261,854,000)			
ccounts payable \$ 2,681,000 \$ 2,259,000 ccrued clinical trial site fees 1,762,000 2,666,000 ccrued payroll and related costs 1,773,000 1,623,000 otes payable, current portion and net of 1,946,000 1,893,000 eferred revenue 47,000 78,000 eferred government contract revenue 47,000 78,000 ustomer deposits 2,191,000 2,618,000 ther current liabilities 1,039,000 860,000 otes payable, less current portion and net 15,158,000 14,403,000 of discount 712,000 1,315,000 - eferred revenue 712,000 1,315,000 - otter long-term liabilities 469,000 210,000 - ommitments and contingencies - - - rocKHOLDERS' EQUITY: - - - - referred stock-\$0.001 par value; authorized - - - 325,000,000 shares; non-voting; nil shares - - - outstanding - - - - 55,784,955 and 53,094,896, respectively		onaudiced	
ccrued clinical trial site fees 1,762,000 2,666,000 ccrued payroll and related costs 1,773,000 1,623,000 otes payable, current portion and net of 1,946,000 1,893,000 discount 1,946,000 1,893,000 eferred revenue 3,719,000 2,406,000 eferred government contract revenue 47,000 78,000 ustomer deposits 2,191,000 2,618,000 ther current liabilities 1,039,000 860,000 Total current liabilities 15,158,000 14,403,000 of discount 712,000 1,315,000 eferred revenue 125,000 - of discount 712,000 1,315,000 eferred revenue 125,000 - ther long-term liabilities 469,000 210,000 ommitments and contingencies - - TOCKHOLDERS' EQUITY: - - referred stock-\$0.001 par value; authorized - - 325,000,000 shares; outstanding - - - 55,784,955 and 53,094,896, respectively 56,000 53,000 ccumulated deficit (26	-	onaudiced	
ccrued payroll and related costs1,773,0001,623,000otes payable, current portion and net of discount1,946,0001,893,000eferred revenue3,719,0002,406,000eferred government contract revenue47,00078,000ustomer deposits2,191,0002,618,000ther current liabilities1,039,000860,000Total current liabilities15,158,00014,403,000otes payable, less current portion and net712,0001,315,000of discount712,0001,315,000-ther long-term liabilities469,000210,000ommitments and contingenciesTOCKHOLDERS' EQUITY:referred stock-\$0.001 par value; authorized325,000,000 shares; outstanding325,000,000 shares; outstanding55,784,955 and 53,094,896, respectively56,00053,000dditional paid-in capital282,330,000275,208,000ccumulated deficit(269,549,000)(261,854,000)	CURRENT LIABILITIES:		
botes payable, current portion and net of discount 1,946,000 1,893,000 eferred revenue 3,719,000 2,406,000 eferred government contract revenue 47,000 78,000 ustomer deposits 2,191,000 2,618,000 ther current liabilities 1,039,000 860,000 Total current liabilities 15,158,000 14,403,000 otes payable, less current portion and net 712,000 1,315,000 of discount 712,000 1,315,000 - eferred revenue 125,000 - - ther long-term liabilities 469,000 210,000 ommitments and contingencies 70CKHOLDERS' EQUITY: - - referred stock-\$0.001 par value; authorized - - - 5,000,000 shares; non-voting; nil shares - - - outstanding - - - - ommon stock-\$0.001 par value; authorized 325,000 53,000 53,000 325,000,000 shares; outstanding - - - - 55,784,955 and 53,094,896, respectively 56,000 53,000	CURRENT LIABILITIES: Accounts payable	\$2,681,000	
discount 1,946,000 1,893,000 eferred revenue 3,719,000 2,406,000 eferred government contract revenue 47,000 78,000 ustomer deposits 2,191,000 2,618,000 ther current liabilities 1,039,000 860,000 Total current liabilities 15,158,000 14,403,000 otes payable, less current portion and net 712,000 1,315,000 of discount 712,000 1,315,000 eferred revenue 125,000 - ther long-term liabilities 469,000 210,000 ommitments and contingencies 7000 2,000 TOCKHOLDERS' EQUITY: - - referred stock-\$0.001 par value; authorized - - 5,000,000 shares; non-voting; nil shares - - outstanding - - - ottomi stock-\$0.001 par value; authorized 325,000 53,000 53,000 325,000,000 shares; outstanding - 56,000 53,000 275,208,000 cumulated deficit (269,549,000) (261,854,000) -	CURRENT LIABILITIES: Accounts payable S Accrued clinical trial site fees	\$ 2,681,000 1,762,000	2,666,000
eferred revenue3,719,0002,406,000eferred government contract revenue47,00078,000ustomer deposits2,191,0002,618,000ther current liabilities1,039,000860,000Total current liabilities15,158,00014,403,000otes payable, less current portion and net712,0001,315,000of discount712,0001,315,000-ther long-term liabilities469,000210,000ommitments and contingencies469,000210,000TOCKHOLDERS' EQUITY:referred stock-\$0.001 par value; authorized50,000,000 shares; non-voting; nil sharesoutstanding00mmon stock-\$0.001 par value; authorized56,00053,000325,000,000 shares; outstanding -55,784,955 and 53,094,896, respectively56,00053,000cumulated deficit(269,549,000)(261,854,000)	CURRENT LIABILITIES: Accounts payable Accrued clinical trial site fees Accrued payroll and related costs	\$ 2,681,000 1,762,000	2,666,000
eferred government contract revenue47,00078,000ustomer deposits2,191,0002,618,000ther current liabilities1,039,000860,000Total current liabilities15,158,00014,403,000of discount712,0001,315,000eferred revenue125,000-ther long-term liabilities469,000210,000ommitments and contingencies210,000-TOCKHOLDERS' EQUITY:referred stock-\$0.001 par value; authorized325,000,000 shares; outstanding55,784,955 and 53,094,896, respectively56,00053,000dditional paid-in capital282,330,000275,208,000ccumulated deficit(269,549,000)(261,854,000)	CURRENT LIABILITIES: Accounts payable Accrued clinical trial site fees Accrued payroll and related costs Notes payable, current portion and net of	\$ 2,681,000 1,762,000 1,773,000	2,666,000 1,623,000
ustomer deposits2,191,0002,618,000ther current liabilities1,039,000860,000Total current liabilities15,158,00014,403,000otes payable, less current portion and net15,158,0001,315,000of discount712,0001,315,000eferred revenue125,000-ther long-term liabilities469,000210,000ommitments and contingencies70CKHOLDERS' EQUITY:-referred stock-\$0.001 par value; authorized50,000,000 shares; non-voting; nil sharesoutstanding55,784,955 and 53,094,896, respectively56,00053,000dditional paid-in capital282,330,000275,208,000ccumulated deficit(269,549,000)(261,854,000)	CURRENT LIABILITIES: Accounts payable Accrued clinical trial site fees Accrued payroll and related costs Notes payable, current portion and net of discount	\$ 2,681,000 1,762,000 1,773,000 1,946,000	2,666,000 1,623,000 1,893,000
ther current liabilities 1,039,000 860,000 Total current liabilities 15,158,000 14,403,000 otes payable, less current portion and net of discount 712,000 1,315,000 eferred revenue 125,000 - ther long-term liabilities 469,000 210,000 ommitments and contingencies TOCKHOLDERS' EQUITY: referred stock-\$0.001 par value; authorized 5,000,000 shares; non-voting; nil shares outstanding - ommon stock-\$0.001 par value; authorized 325,000,000 shares; outstanding - 55,784,955 and 53,094,896, respectively 56,000 53,000 dditional paid-in capital 282,330,000 275,208,000 ccumulated deficit (269,549,000) (261,854,000)	CURRENT LIABILITIES: Accounts payable Accrued clinical trial site fees Accrued payroll and related costs Notes payable, current portion and net of discount	<pre>\$ 2,681,000 1,762,000 1,773,000 1,946,000 3,719,000</pre>	2,666,000 1,623,000 1,893,000 2,406,000
Total current liabilities15,158,00014,403,000otes payable, less current portion and net12,0001,315,000of discount712,0001,315,000eferred revenue125,000-ther long-term liabilities469,000210,000ommitments and contingencies469,000210,000TOCKHOLDERS' EQUITY:referred stock-\$0.001 par value; authorized-5,000,000 shares; non-voting; nil sharesoutstandingommon stock-\$0.001 par value; authorized325,000,000 shares; outstanding55,784,955 and 53,094,896, respectively56,00053,000dditional paid-in capital282,330,000275,208,000ccumulated deficit(269,549,000)(261,854,000)	CURRENT LIABILITIES: Accounts payable Accrued clinical trial site fees Accrued payroll and related costs Notes payable, current portion and net of discount Deferred revenue Deferred government contract revenue	<pre>\$ 2,681,000 1,762,000 1,773,000 1,946,000 3,719,000 47,000</pre>	2,666,000 1,623,000 1,893,000 2,406,000 78,000
Total current liabilities15,158,00014,403,000otes payable, less current portion and net712,0001,315,000of discount712,0001,315,000eferred revenue125,000-ther long-term liabilities469,000210,000ommitments and contingencies469,000210,000TOCKHOLDERS' EQUITY:referred stock-\$0.001 par value; authorized-soutstandingommon stock-\$0.001 par value; authorized-325,000,000 shares; outstanding -56,00053,000cumulated deficit282,330,000275,208,000cumulated deficit(269,549,000)(261,854,000)	CURRENT LIABILITIES: Accounts payable Accrued clinical trial site fees Accrued payroll and related costs Notes payable, current portion and net of discount Deferred revenue Deferred government contract revenue	<pre>\$ 2,681,000 1,762,000 1,773,000 1,946,000 3,719,000 47,000</pre>	2,666,000 1,623,000 1,893,000 2,406,000 78,000
otes payable, less current portion and net712,0001,315,000of discount712,0001,315,000eferred revenue125,000-ther long-term liabilities469,000210,000ommitments and contingencies469,000210,000TOCKHOLDERS' EQUITY:referred stock-\$0.001 par value; authorized-5,000,000 shares; non-voting; nil sharesoutstandingommon stock-\$0.001 par value; authorized325,000,000 shares; outstanding -56,00053,00055,784,955 and 53,094,896, respectively56,00053,000dditional paid-in capital282,330,000275,208,000ccumulated deficit(269,549,000)(261,854,000)	CURRENT LIABILITIES: Accounts payable Accrued clinical trial site fees Accrued payroll and related costs Notes payable, current portion and net of discount Deferred revenue Deferred government contract revenue Customer deposits	<pre>\$ 2,681,000 1,762,000 1,773,000 1,946,000 3,719,000 47,000 2,191,000 1,039,000</pre>	2,666,000 1,623,000 1,893,000 2,406,000 78,000 2,618,000 860,000
of discount712,0001,315,000eferred revenue125,000-ther long-term liabilities469,000210,000ommitments and contingencies469,000210,000TOCKHOLDERS' EQUITY:referred stock-\$0.001 par value; authorized5,000,000 shares; non-voting; nil sharesoutstandingommon stock-\$0.001 par value; authorized325,000,000 shares; outstanding55,784,955 and 53,094,896, respectively56,00053,000dditional paid-in capital282,330,000275,208,000ccumulated deficit(269,549,000)(261,854,000)	CURRENT LIABILITIES: Accounts payable Accrued clinical trial site fees Accrued payroll and related costs Notes payable, current portion and net of discount Deferred revenue Deferred government contract revenue Customer deposits Other current liabilities	<pre>\$ 2,681,000 1,762,000 1,773,000 1,946,000 3,719,000 47,000 2,191,000 1,039,000</pre>	2,666,000 1,623,000 1,893,000 2,406,000 78,000 2,618,000 860,000
eferred revenue125,000ther long-term liabilities469,000ommitments and contingenciesTOCKHOLDERS' EQUITY:referred stock-\$0.001 par value; authorized5,000,000 shares; non-voting; nil sharesoutstandingommon stock-\$0.001 par value; authorized325,000,000 shares; outstanding -55,784,955 and 53,094,896, respectively56,000dditional paid-in capitalccumulated deficit(269,549,000)(261,854,000)	CURRENT LIABILITIES: Accounts payable Accrued clinical trial site fees Accrued payroll and related costs Notes payable, current portion and net of discount Deferred revenue Deferred government contract revenue Customer deposits Other current liabilities Total current liabilities	<pre>\$ 2,681,000 1,762,000 1,773,000 1,946,000 3,719,000 47,000 2,191,000 1,039,000</pre>	2,666,000 1,623,000 1,893,000 2,406,000 78,000 2,618,000 860,000
ther long-term liabilities 469,000 210,000 ommitments and contingencies TOCKHOLDERS' EQUITY: referred stock-\$0.001 par value; authorized 5,000,000 shares; non-voting; nil shares outstanding ommon stock-\$0.001 par value; authorized 325,000,000 shares; outstanding - 55,784,955 and 53,094,896, respectively 56,000 53,000 dditional paid-in capital 282,330,000 275,208,000 ccumulated deficit (269,549,000) (261,854,000)	CURRENT LIABILITIES: Accounts payable Accrued clinical trial site fees Accrued payroll and related costs Notes payable, current portion and net of discount Deferred revenue Deferred government contract revenue Customer deposits Dther current liabilities Total current liabilities Notes payable, less current portion and net	<pre>\$ 2,681,000 1,762,000 1,773,000 1,946,000 3,719,000 47,000 2,191,000 1,039,000 15,158,000</pre>	2,666,000 1,623,000 2,406,000 78,000 2,618,000 860,000 14,403,000
ommitments and contingencies TOCKHOLDERS' EQUITY: referred stock-\$0.001 par value; authorized 5,000,000 shares; non-voting; nil shares outstanding ommon stock-\$0.001 par value; authorized 325,000,000 shares; outstanding - 55,784,955 and 53,094,896, respectively 56,000 53,000 dditional paid-in capital 282,330,000 275,208,000 ccumulated deficit (269,549,000) (261,854,000)	CURRENT LIABILITIES: Accounts payable Accrued clinical trial site fees Accrued payroll and related costs Notes payable, current portion and net of discount Deferred revenue Deferred government contract revenue Customer deposits Other current liabilities Total current liabilities Notes payable, less current portion and net of discount	<pre>\$ 2,681,000 1,762,000 1,773,000 1,946,000 3,719,000 47,000 2,191,000 1,039,000 15,158,000 712,000</pre>	2,666,000 1,623,000 2,406,000 78,000 2,618,000 860,000 14,403,000
TOCKHOLDERS' EQUITY: referred stock-\$0.001 par value; authorized 5,000,000 shares; non-voting; nil shares outstanding ommon stock-\$0.001 par value; authorized 325,000,000 shares; outstanding - 55,784,955 and 53,094,896, respectively 56,000 53,000 dditional paid-in capital 282,330,000 275,208,000 ccumulated deficit (269,549,000) (261,854,000)	CURRENT LIABILITIES: Accounts payable Accrued clinical trial site fees Accrued payroll and related costs Notes payable, current portion and net of discount Deferred revenue Deferred government contract revenue Customer deposits Other current liabilities Total current liabilities Notes payable, less current portion and net of discount Deferred revenue	<pre>\$ 2,681,000 1,762,000 1,773,000 1,946,000 3,719,000 47,000 2,191,000 1,039,000 15,158,000 712,000 125,000</pre>	2,666,000 1,623,000 1,893,000 2,406,000 78,000 2,618,000 860,000 14,403,000 1,315,000
referred stock-\$0.001 par value; authorized 5,000,000 shares; non-voting; nil shares outstanding ommon stock-\$0.001 par value; authorized 325,000,000 shares; outstanding - 55,784,955 and 53,094,896, respectively 56,000 53,000 dditional paid-in capital 282,330,000 275,208,000 ccumulated deficit (269,549,000) (261,854,000)	CURRENT LIABILITIES: Accounts payable Accrued clinical trial site fees Accrued payroll and related costs Notes payable, current portion and net of discount Deferred revenue Deferred government contract revenue Customer deposits Dther current liabilities Total current liabilities Notes payable, less current portion and net of discount Deferred revenue Dther long-term liabilities	<pre>\$ 2,681,000 1,762,000 1,773,000 1,946,000 3,719,000 47,000 2,191,000 1,039,000 15,158,000 712,000 125,000</pre>	2,666,000 1,623,000 1,893,000 2,406,000 78,000 2,618,000 860,000 14,403,000 1,315,000
5,000,000 shares; non-voting; nil shares outstanding ommon stock-\$0.001 par value; authorized 325,000,000 shares; outstanding - 55,784,955 and 53,094,896, respectively 56,000 53,000 dditional paid-in capital 282,330,000 275,208,000 ccumulated deficit (269,549,000) (261,854,000)	CURRENT LIABILITIES: Accounts payable Accrued clinical trial site fees Accrued payroll and related costs Notes payable, current portion and net of discount Deferred revenue Deferred government contract revenue Customer deposits Other current liabilities Total current liabilities Notes payable, less current portion and net of discount Deferred revenue Other long-term liabilities Commitments and contingencies	<pre>\$ 2,681,000 1,762,000 1,773,000 1,946,000 3,719,000 47,000 2,191,000 1,039,000 15,158,000 712,000 125,000</pre>	2,666,000 1,623,000 1,893,000 2,406,000 78,000 2,618,000 860,000 14,403,000 1,315,000
outstanding - - ommon stock-\$0.001 par value; authorized - - 325,000,000 shares; outstanding - - - 55,784,955 and 53,094,896, respectively 56,000 53,000 dditional paid-in capital 282,330,000 275,208,000 ccumulated deficit (269,549,000) (261,854,000)	CURRENT LIABILITIES: Accounts payable Accrued clinical trial site fees Accrued payroll and related costs Notes payable, current portion and net of discount Deferred revenue Deferred government contract revenue Customer deposits Other current liabilities Total current liabilities Notes payable, less current portion and net of discount Deferred revenue Dther long-term liabilities Commitments and contingencies STOCKHOLDERS' EQUITY:	<pre>\$ 2,681,000 1,762,000 1,773,000 1,946,000 3,719,000 47,000 2,191,000 1,039,000 15,158,000 712,000 125,000</pre>	2,666,000 1,623,000 1,893,000 2,406,000 78,000 2,618,000 860,000 14,403,000 1,315,000
ommon stock-\$0.001 par value; authorized 325,000,000 shares; outstanding - 55,784,955 and 53,094,896, respectively 56,000 53,000 dditional paid-in capital 282,330,000 275,208,000 ccumulated deficit (269,549,000) (261,854,000)	CURRENT LIABILITIES: Accounts payable Accrued clinical trial site fees Accrued payroll and related costs Notes payable, current portion and net of discount Deferred revenue Deferred government contract revenue Customer deposits Other current liabilities Total current liabilities Notes payable, less current portion and net of discount Deferred revenue Other long-term liabilities Commitments and contingencies STOCKHOLDERS' EQUITY: Preferred stock-\$0.001 par value; authorized	<pre>\$ 2,681,000 1,762,000 1,773,000 1,946,000 3,719,000 47,000 2,191,000 1,039,000 15,158,000 712,000 125,000</pre>	2,666,000 1,623,000 1,893,000 2,406,000 78,000 2,618,000 860,000 14,403,000 1,315,000
325,000,000 shares; outstanding - 55,784,955 and 53,094,896, respectively 56,000 53,000 dditional paid-in capital 282,330,000 275,208,000 ccumulated deficit (269,549,000) (261,854,000)	CURRENT LIABILITIES: Accounts payable Accrued clinical trial site fees Accrued payroll and related costs Notes payable, current portion and net of discount Deferred revenue Deferred government contract revenue Customer deposits Other current liabilities Total current liabilities Notes payable, less current portion and net of discount Deferred revenue Other long-term liabilities STOCKHOLDERS' EQUITY: Preferred stock-\$0.001 par value; authorized 5,000,000 shares; non-voting; nil shares	<pre>\$ 2,681,000 1,762,000 1,773,000 1,946,000 3,719,000 47,000 2,191,000 1,039,000 15,158,000 712,000 125,000</pre>	2,666,000 1,623,000 1,893,000 2,406,000 78,000 2,618,000 860,000 14,403,000 1,315,000
55,784,955 and 53,094,896, respectively 56,000 53,000 dditional paid-in capital 282,330,000 275,208,000 ccumulated deficit (269,549,000) (261,854,000)	CURRENT LIABILITIES: Accounts payable Accrued clinical trial site fees Accrued payroll and related costs Notes payable, current portion and net of discount Deferred revenue Deferred government contract revenue Customer deposits Other current liabilities Total current liabilities Notes payable, less current portion and net of discount Deferred revenue Other long-term liabilities STOCKHOLDERS' EQUITY: Preferred stock-\$0.001 par value; authorized 5,000,000 shares; non-voting; nil shares outstanding	<pre>\$ 2,681,000 1,762,000 1,773,000 1,946,000 3,719,000 47,000 2,191,000 1,039,000 15,158,000 712,000 125,000</pre>	2,666,000 1,623,000 1,893,000 2,406,000 78,000 2,618,000 860,000 14,403,000 1,315,000
dditional paid-in capital 282,330,000 275,208,000 ccumulated deficit (269,549,000) (261,854,000)	CURRENT LIABILITIES: Accounts payable Accrued clinical trial site fees Accrued payroll and related costs Notes payable, current portion and net of discount Deferred revenue Deferred government contract revenue Customer deposits Other current liabilities Total current liabilities Notes payable, less current portion and net of discount Deferred revenue Other long-term liabilities STOCKHOLDERS' EQUITY: Preferred stock-\$0.001 par value; authorized 5,000,000 shares; non-voting; nil shares outstanding Common stock-\$0.001 par value; authorized	<pre>\$ 2,681,000 1,762,000 1,773,000 1,946,000 3,719,000 47,000 2,191,000 1,039,000 15,158,000 712,000 125,000</pre>	2,666,000 1,623,000 1,893,000 2,406,000 78,000 2,618,000 860,000 14,403,000 1,315,000
ccumulated deficit (269,549,000) (261,854,000)	CURRENT LIABILITIES: Accounts payable Accrued clinical trial site fees Accrued payroll and related costs Notes payable, current portion and net of discount Deferred revenue Deferred government contract revenue Customer deposits Other current liabilities Total current liabilities Notes payable, less current portion and net of discount Deferred revenue Other long-term liabilities STOCKHOLDERS' EQUITY: Preferred stock-\$0.001 par value; authorized 5,000,000 shares; non-voting; nil shares outstanding Common stock-\$0.001 par value; authorized 325,000,000 shares; outstanding -	<pre>\$ 2,681,000 1,762,000 1,773,000 1,946,000 3,719,000 2,191,000 1,039,000 15,158,000 712,000 125,000 469,000</pre>	2,666,000 1,623,000 2,406,000 78,000 2,618,000 860,000 1,315,000 210,000
	CURRENT LIABILITIES: Accounts payable Accrued clinical trial site fees Accrued payroll and related costs Notes payable, current portion and net of discount Deferred revenue Deferred government contract revenue Customer deposits Other current liabilities Total current liabilities Notes payable, less current portion and net of discount Deferred revenue Other long-term liabilities STOCKHOLDERS' EQUITY: Preferred stock-\$0.001 par value; authorized 5,000,000 shares; non-voting; nil shares outstanding Common stock-\$0.001 par value; authorized 325,000,000 shares; outstanding - 55,784,955 and 53,094,896, respectively	<pre>\$ 2,681,000 1,762,000 1,773,000 1,946,000 3,719,000 2,191,000 1,039,000 15,158,000 712,000 125,000 469,000</pre>	2,666,000 1,623,000 2,406,000 78,000 2,618,000 860,000 1,315,000 1,315,000
	Accrued clinical trial site fees Accrued payroll and related costs Notes payable, current portion and net of discount Deferred revenue Deferred government contract revenue Customer deposits Other current liabilities Total current liabilities Notes payable, less current portion and net of discount Deferred revenue Other long-term liabilities STOCKHOLDERS' EQUITY: Preferred stock-\$0.001 par value; authorized 5,000,000 shares; non-voting; nil shares outstanding Common stock-\$0.001 par value; authorized 325,000,000 shares; outstanding - 55,784,955 and 53,094,896, respectively Additional paid-in capital	<pre>\$ 2,681,000 1,762,000 1,773,000 1,773,000 3,719,000 2,191,000 1,039,000 15,158,000 712,000 125,000 469,000 </pre>	2,666,000 1,623,000 2,406,000 78,000 2,618,000 860,000 1,315,000 1,315,000
10001 SCOCMOTUCES EQUICY 12,037,000 13,407,000	CURRENT LIABILITIES: Accounts payable Accrued clinical trial site fees Accrued payroll and related costs Notes payable, current portion and net of discount Deferred revenue Deferred government contract revenue Customer deposits Other current liabilities Total current liabilities Notes payable, less current portion and net of discount Deferred revenue Other long-term liabilities STOCKHOLDERS' EQUITY: Preferred stock-\$0.001 par value; authorized 5,000,000 shares; non-voting; nil shares outstanding Common stock-\$0.001 par value; authorized 325,000,000 shares; outstanding - 55,784,955 and 53,094,896, respectively	<pre>\$ 2,681,000 1,762,000 1,773,000 1,773,000 3,719,000 2,191,000 1,039,000 15,158,000 712,000 125,000 469,000 </pre>	2,666,000 1,623,000 2,406,000 78,000 2,618,000 860,000 1,315,000 1,315,000
	CURRENT LIABILITIES: Accounts payable Accrued clinical trial site fees Accrued payroll and related costs Notes payable, current portion and net of discount Deferred revenue Deferred government contract revenue Customer deposits Other current liabilities Total current liabilities Notes payable, less current portion and net of discount Deferred revenue Other long-term liabilities STOCKHOLDERS' EQUITY: Preferred stock-\$0.001 par value; authorized 5,000,000 shares; non-voting; nil shares outstanding Common stock-\$0.001 par value; authorized 325,000,000 shares; outstanding - 55,784,955 and 53,094,896, respectively Additional paid-in capital Accumulated deficit	<pre>\$ 2,681,000 1,762,000 1,773,000 1,946,000 3,719,000 2,191,000 1,039,000 15,158,000 712,000 125,000 469,000 </pre>	2,666,000 1,623,000 2,406,000 78,000 2,618,000 860,000 1,315,000 1,315,000 210,000

Contact: Amy Figueroa Peregrine Pharmaceuticals (800) 987-8256 <u>info@peregrineinc.com</u>

SOURCE: Peregrine Pharmaceuticals

mailto:info@peregrineinc.com

Copyright 2010 Marketwire, Inc., All rights reserved.

News Provided by COMTEX